Palisade Bio, Inc. (PALI) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Palisade Bio, Inc. (PALI) closed at USD 1.54 on 2026-10-15, a change of -27.4 % over the past year, with a market capitalization of USD 245.72M.

Palisade Bio, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Palisade Bio, Inc. key figures

Previous close

USD 1.54 (2026-10-15)

1-year change

-27.4 %

Market cap

USD 245.72M

Enterprise value

USD 120.55M

P/E ratio (trailing)

2.35

P/E ratio (forward)

-4.97

EPS (trailing)

0.60

EPS (forward)

-0.28

PEG ratio

n/a

Price to book

2.01

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.47

Employees

14

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Palisade Bio, Inc.

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Palisade Bio, Inc. and compare it with other stocks.